Navigation Links
Amgen Announces Webcast of 2010 Third Quarter Financial Results
Date:10/20/2010

THOUSAND OAKS, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.  The webcast will be archived and available for replay 72 hours after the event.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramaticall
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
2. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
5. Amgen to Present at the UBS Global Life Sciences Conference
6. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
7. Amgen to Present at the Baird Healthcare Conference
8. Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
9. Amgen to Present at the 28th Annual JP Morgan Healthcare Conference
10. Amgen Resolves EPO Patent Dispute With Roche
11. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... May 15, 2012  Cardium Therapeutics (NYSE Amex: ... UK-based Angel Biomedical Limited, a subsidiary of Angel ... contract manufacturer, covering the manufacture of formulated collagen ... for marketing by the U.S. Food and Drug ...
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , ... treatment and diagnosis of cancer, today announced that ... a U.S. multi-center Phase 1b dose-escalation trial of ... cancer patients with advanced solid tumors.  The first ...
Cached Medicine Technology:Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 2Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 3Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 4Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 5Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 6Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 2Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 3Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 4
(Date:4/20/2014)... PHILADELPHIA Researchers may have identified key genes linked ... pain than others, according to a study released today ... Neurology,s 66th Annual Meeting in Philadelphia, April 26 to ... significant because it provides an objective way to understand ... levels," said study author Tobore Onojjighofia, MD, MPH, with ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2
... 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) ... in many cancer tumors, including medulloblastoma, the most common ... most promising targets for cancer therapy. A recent ... be effective in interfering with the cell cycle and ...
... Jens Bangsbo from the Department of Exercise and Sports ... intervention studies involving both men, women and children, who ... results from the studies are so remarkable that the ... are publishing a special edition issue entitled "Football ...
... wind up in ER during major U.S. holidays, researchers find, ... are injured during the holidays, it,s not too many chocolate ... damage, a new study shows. , Rather, it is the ... fall prey to, the researchers from Nationwide Children,s Hospital in ...
... ... Superfruit Companies , ... (Vocus) -- Tahitian Noni International (TNI) announced a new quarter of a million ... other product in the industry will measure up to Tahitian Noni Bioactive Beverages., , , ...
... ... Excellence in Financial Journalism Award from the New York State Society of Certified Public Accountants ... New York, NY ... CFO magazine , won an Excellence in Financial Journalism Award from the New York ...
... ... PeopleStreme Human Capital has announced a collaboration with SkillSoft ... its clients.,We are thrilled to collaborate with SkillSoft to provide SkillSoft’s ... is a clear leader in the provision of our technology enabled ...
Cached Medicine News:Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Most Holiday Injuries to Kids Spurred by Everyday Mishaps 2Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2Health News:CFO magazine Wins Excellence in Financial Journalism Award 2Health News:PeopleStreme Collaborates with SkillSoft for Learning Management Content 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: